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Trans-synaptic zinc mobilization improves social
interaction in two mouse models of autism through
NMDAR activation
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Genetic aspects of autism spectrum disorders (ASDs) have recently been extensively
explored, but environmental inﬂuences that affect ASDs have received considerably less
attention. Zinc (Zn) is a nutritional factor implicated in ASDs, but evidence for a strong
association and linking mechanism is largely lacking. Here we report that trans-synaptic Zn
mobilization rapidly rescues social interaction in two independent mouse models of ASD. In
mice lacking Shank2, an excitatory postsynaptic scaffolding protein, postsynaptic Zn elevation
induced by clioquinol (a Zn chelator and ionophore) improves social interaction. Postsynaptic
Zn is mainly derived from presynaptic pools and activates NMDA receptors (NMDARs)
through postsynaptic activation of the tyrosine kinase Src. Clioquinol also improves social
interaction in mice haploinsufﬁcient for the transcription factor Tbr1, which accompanies
NMDAR activation in the amygdala. These results suggest that trans-synaptic Zn
mobilization induced by clioquinol rescues social deﬁcits in mouse models of ASD through
postsynaptic Src and NMDAR activation.
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A
utism spectrum disorders (ASDs) represent a neurodeve-
lopmental disorder characterized by impaired social
interaction and communication, and restricted and
repetitive behaviour, interest and activity. ASDs affect B1% of
the population and are thought to be strongly inﬂuenced by
genetic factors. A large number of ASD-associated genetic
variations have recently been identiﬁed, indicating that ASDs
represent a genetically heterogeneous family of disorders1–3.
Some of the genetic variations lie along common pathways/
functions, including synaptic transmission, transcriptional
regulation and chromatin remodelling1–3. In addition, studies
using mouse models of ASD carrying these mutations have begun
to suggest possible mechanisms that may underlie the
pathogenesis of ASD, namely glutamatergic dysfunction and an
imbalance between excitatory and inhibitory synapses4–14.
Environmental inﬂuences, such as nutrition, toxins and
poisons, drugs, infection and stress, are thought to have a
signiﬁcant inﬂuence on psychiatric disorders. In ASDs, well-
known examples of environmental inﬂuences include pre- or
perinatal exposure to viruses or teratogens such as valproic
acid and thalidomide15,16. However, studies on additional
environmental inﬂuences and underlying mechanisms are at an
early stage. This contrasts with the rapidly growing evidence
for the contribution of genetic factors to ASDs. Because
environmental factors are highly likely to interact with the
genetic variations of ASD to determine the type, severity and
trajectory of ASD symptoms, a balance between genetic and
environmental causes is required in studies of ASDs.
Zinc (Zn), the second-most abundant trace element with a
critical role in human nutrition and health, regulates a variety of
cellular processes and protein functions. Zn deﬁciency has been
implicated in diverse neurological and psychiatric disorders,
including Alzheimer’s disease, Parkinson’s disease, ASDs, atten-
tion deﬁcit/hyperactivity disorder, schizophrenia, epilepsy and
mood disorders17. The association of Zn with ASDs has been
suggested based on its deﬁciency in individuals with ASDs,
including a recent large cohort of 1,967 children16,18, as well as
the phenotypes of Zn-deﬁcient experimental animals19. This
association is further supported by the potential therapeutic value
of Zn supplementation in ASD treatment17,20. However, strong
evidence supporting the association between Zn deﬁciency and
ASDs is largely unavailable, and the mechanisms underlying the
association remain obscure.
In the synapse, the main pool of Zn ions is presynaptic vesicles
where Zn is in the millimolar range, whereas postsynaptic sites
contain much smaller amounts of Zn (picomolar range)21–24.
Presynaptic free Zn is co-released with glutamate during neuronal
activity and serves to suppress NMDA receptors (NMDARs) in
the synaptic cleft. Some Zn ions enter the postsynaptic sites
through calcium channels, NMDARs and calcium-permeable
AMPA receptors (AMPARs), and regulate target proteins such as
NMDARs and TrkB receptors through mechanisms including
those involving Src family tyrosine kinases (SFKs)25–27. Another
important effector of postsynaptic Zn is Shank (also known as
ProSAP), a family of excitatory postsynaptic scaffolding proteins
with three known members (Shank1/2/3; refs 28,29). Zn binds to
Shank2/3 and enhances their postsynaptic stabilization,
promoting excitatory synapse formation and maturation30.
Shank2/3, members of the Shank family of postsynaptic
scaffolding proteins (also known as ProSAP1/2), have been
implicated in ASDs through human genetic studies31–36 and
mouse model/cultured neuron studies19,30,37–48. Mice carrying
Shank2/3 mutations display diverse dysfunctions at glutamate
synapses40–46,49. One notable change is the reduction in NMDAR
function observed in Shank2 / mice (exons 6þ 7 deletion)45.
In these mice, normalization of NMDAR function with an
NMDAR agonist (D-cycloserine) is associated with the rescue of
impaired social interaction, suggesting that NMDAR
hypofunction might underlie the social deﬁcit in these mice.
Although validation of this hypothesis will require further
analyses, D-cycloserine has also been shown to rescue the
impaired social interaction in mice with a haploinsufﬁciency of
the transcription factor Tbr1 (T-box brain 1; ref. 50), which
positively regulates the expression of Grin2b (ref. 51), encoding
the GluN2B subunit of NMDARs.
In the present study, we demonstrate that trans-synaptic
Zn mobilization by clioquinol, a Zn chelator and ionophore
(termed CQ hereafter), rescues the social interaction deﬁcits in
Shank2 / and Tbr1þ / mice. CQ mobilizes Zn from enriched
presynaptic pools to postsynaptic sites, where it enhances
NMDAR function through Src activation. These results indicate
that postsynaptic Zn rescues social interaction deﬁcits in distinct
mouse models of ASDs, and suggest that reduced NMDAR
function is associated with ASDs.
Results
CQ rapidly improves social interaction in Shank2 / mice.
Based on the close associations among Zn, NMDAR, Shank and
ASD mentioned above, we reasoned that Zn delivered to post-
synaptic compartments might rescue the reduced NMDAR
function and ASD-like behaviours observed in Shank2 / mice.
To test this idea, we ﬁrst intraperitoneally (i.p.) injected
Shank2 / mice with CQ (30mg kg 1), a lipophilic Zn chelator
(KdE10 7) and ionophore that readily crosses the blood–brain
barrier and mobilizes Zn down a concentration gradient52. We
chose systemic administration of CQ because dietary Zn is known
to have poor bioavailability and side effects including gastric
irritation17,53.
Two hours after CQ treatment, the mice were subjected to the
three-chamber social interaction test, which compares the
preference of a mouse for a stranger mouse versus a novel
inanimate object. We found that Shank2 / mice displayed
reduced social interaction compared with wild-type (WT) mice,
as determined by time spent exploring/snifﬁng the target and the
social preference indices derived from exploration time (see ﬁgure
legend for details) (Fig. 1a–c and Supplementary Fig. 1a,d–i),
consistent with previous results from untreated Shank2 / and
WT mice45. This impairment was improved by CQ treatment. In
contrast, social interaction in WT mice was not affected by CQ.
Notably, Shank2 / mice in the chamber with a stranger often
spent time in other activities such as jumping, contrary to WT
mice, as reﬂected in the relatively low correlation between
exploration time and chamber time (Supplementary Fig. 2), and
showed an apparent lack of CQ-dependent improvement in social
interaction, as determined by the time spent in chamber and the
preference index derived from chamber time (Supplementary
Fig. 1b,c).
When social novelty recognition was determined in the same
three-chamber test, by measuring the preference for a previously
encountered stranger mouse versus a new stranger mouse,
Shank2 / mice showed levels of social novelty recognition
comparable to those in WT mice (Fig. 1d–f and Supplementary
Fig. 1j–m), as reported previously45. In addition, CQ had no effect
on social novelty recognition in both WT and Shank2 / mice.
The CQ-dependent rescue of social interaction in Shank2 /
mice but no effect of CQ on WT mice is unlikely attributable to
differences in the amount of free Zn available for CQ binding in
these mice, because total levels of free Zn measured with the
ﬂuorescent dye TFL-Zn were not different (Supplementary
Fig. 3a,b). In addition, the levels of Zn transporter 3 (ZnT3), a
protein required for Zn transport into presynaptic vesicles54,
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which is the main pool of free Zn in the brain, were similar
between genotypes (Supplementary Fig. 3c). Finally, whole-brain
levels of Zn, Cu or Fe were not different between WT and
Shank2 / mice, which is in line with the above-mentioned
TFL-Zn staining result, and, more importantly, 2-hr CQ treat-
ment did not cause an acute reduction in the levels of these
metals in WT or Shank2 / mice (Supplementary Fig. 4a–c),
suggesting that the chelating activity of CQ unlikely contributes
to the observed social rescue.
In repetitive behaviour assays, vehicle-treated Shank2 /
mice showed increased jumping behaviour but normal grooming
in their home cages, relative to vehicle-treated WT mice,
consistent with the previous results45; these behaviours were
unaffected by CQ (Fig. 1g,h and Supplementary Fig. 5a–d).
Similarly, CQ did not affect repetitive behaviours in WT mice.
In the open-ﬁeld test, Shank2 / mice displayed increased
locomotor activity relative to WT mice, as previously reported.
This hyperactivity was not attenuated by CQ (Fig. 1i,j). Notably,
Shank2 / mice spent less time in the centre region of the
open-ﬁeld arena, a measure of anxiety-like behaviour. However,
CQ had no effect on the centre-region time in these mice
(Supplementary Fig. 5e). CQ did not affect the repetitive
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Figure 1 | CQ treatment rapidly improves social interaction in Shank2 / mice. (a–f) CQ improves social interaction in Shank2 / (KO) mice, but has
no effect on WTmice (a–c). Note that levels of social novelty recognition are similar in WT and Shank2 / mice, and that CQ does not affect social
novelty recognition in these mice (d–f). Mice were injected with CQ (30mg kg 1; i.p.), or vehicle, 2 h before behavioural tests. Heat maps in (a,d)
represent examples of mouse movements. The social preference index from exploration time represents the numerical difference between the times spent
exploring or snifﬁng the two targets (S1/stranger versus O/object or S2/new stranger versus S1/previous stranger) divided by total time spent 100. V,
vehicle; C, CQ. (n¼ 28 for WT-V and WT-C, and 25 for KO-V and KO-C); **Po0.01, ***Po0.001; Kruskal–Wallis one-way analysis of variance (ANOVA)
with Dunn’s post hoc test). (g,h) CQ has no effect on jumping or grooming behaviour in Shank2 / mice. (n¼ 10 for WT-V and WT-C, and 11 for KO-V
and KO-C, *Po0.05, two-way ANOVA and Kruskal–Wallis one-way ANOVA with Dunn’s post hoc test). (i,j) CQ does not normalize hyperactivity in
Shank2 / mice. (n¼ 23 for WT-V and WT-C, and 21 for KO-V and KO-C; ***Po0.001, two-way ANOVA and Kruskal–Wallis one-way ANOVA with
Dunn’s post hoc test). Data in all panels with error bars represent mean±s.e.m. NS, not signiﬁcant.
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behaviour, locomotor activity or anxiety-like behaviour of WT
mice. Together, these results suggest that CQ improves social
interaction but has no effect on social novelty recognition,
repetitive behaviour, hyperactivity or anxiety-like behaviour in
Shank2 / mice.
NMDAR function at Shank2 / synapses is restored by CQ.
The CQ-dependent rescue of social interaction deﬁcits in
Shank2 / mice could involve normalization of the reported
reduction in NMDAR function in these mice45. Consistent with
this possibility, we found that CQ treatment restored normal
levels of NMDAR function at Shank2 / hippocampal Schaffer
collateral-CA1 pyramidal (SC-CA1) synapses, as determined by
the ratio of NMDAR- to AMPAR-evoked excitatory postsynaptic
currents (NMDA/AMPA ratio of eEPSCs; Fig. 2a). CQ, however,
had no effect at WT synapses. In addition, CQ reversed the
reduced tetanus-induced long-term potentiation (LTP), known to
require NMDAR activity, at Shank2 / SC-CA1 synapses, but
had no effect on LTP at WT synapses (Fig. 2b). These results
indicate that CQ restores NMDAR function at Shank2 /
hippocampal SC-CA1 synapses.
We next measured the time course of CQ-dependent NMDAR
activation at Shank2 / synapses. In these experiments, we
treated Shank2 / hippocampal slices with CQ for 20min (in
contrast to the continuous bath application for experiments
described above) while monitoring NMDAR-mediated ﬁeld
excitatory postsynaptic potentials (NMDA-fEPSPs) before,
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Figure 2 | CQ restores NMDAR function at Shank2 / synapses. (a) CQ (4 mM) normalizes the NMDA/AMPA ratio at Shank2 / hippocampal
SC-CA1 synapses (P17–25), as measured by NMDA- and AMPA-eEPSCs. Representative eEPSC traces recorded at  70 andþ40mV. NMDA-eEPSCs
were measured at þ40mV holding potential, 60ms after the stimulation. (n¼ 14 cells (from 10 animals) for WT-V, 11 (7) for WT-C, 12 (8) for KO-V and
12 (7) for KO-C, *Po0.05; one-way analysis of variance (ANOVA) with Tukey’s post hoc test). (b) CQ (4 mM) restores LTP, induced by tetanus (100Hz), at
Shank2 / hippocampal SC-CA1 synapses (3–5 weeks), as measured by fEPSPs. (n¼ 13 slices (from 8 animals) for WT-V, 12 (5) for WT-C, 13 (7) for KO-
V and 11 (5) for KO-C; *Po0.05; one-way ANOVA with Tukey’s post hoc test). (c) CQ (4mM, 20min) enhances NMDAR function at WTand Shank2 /
hippocampal SC-CA1 synapses, as measured by NMDA-fEPSPs. (n¼ 8 slices (from 7 animals) for WT and 8 (7) for KO; **Po0.01; Student’s t-test) The
labels a and b indicate 5-min duration before CQ and the end of recording, respectively. (d,e) CQ (4 mM, 20min) enhances NMDAR function at WT and
Shank2 / hippocampal SC-CA1 synapses, as determined by simultaneous measurements of NMDA- and AMPA-eEPSCs at 40mV. NMDA-eEPSCs
were measured at 60ms after stimulation. D-AP5 (50 mM, 10min) was used to test NMDAR dependence. The labels (a–c) indicate 5-min duration before
and after CQ, and at the end of recording, respectively. (n¼4 cells (three slices) for WTand 5 cells (four slices) for KO; *Po0.05, **Po0.01, ***Po0.001;
Student’s t-test, compared with the 5-min duration before CQ). Data in all panels with error bars represent mean±s.e.m. NS, not signiﬁcant.
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during and after CQ treatment. With CQ treatment, the initial
slopes of NMDA-fEPSPs at Shank2 / SC-CA1 synapses
gradually increased to B150% of baseline levels and remained
elevated, a response similar to that observed in WT slices
(Fig. 2c). In contrast to NMDA-fEPSPs, AMPAR-mediated
fEPSPs (AMPA-fEPSPs) were not affected by CQ treatment
(Supplementary Fig. 6a). CQ also had no effect on AMPAR-
related input–output ratio (AMPA-fEPSP slopes plotted against
ﬁbre volleys) or paired-pulse ratio at SC-CA1 synapses
(Supplementary Fig. 6b,c).
To further conﬁrm the CQ-dependent NMDAR activation, we
simultaneously measured NMDA- and AMPA-eEPSCs using
patch-clamp recordings. At a holding potential of  40mV, CQ
increased NMDA-eEPSCs at Shank2 / SC-CA1 synapses, a
result similar to that observed at WT synapses (Fig. 2d,e). The
NMDAR antagonist D-AP5 signiﬁcantly reduced NMDA-eEPSCs
but not AMPA-eEPSCs, indicating that these events are NMDAR
dependent. In contrast, AMPA-eEPSCs were not affected by CQ
treatment (Fig. 2d,e). Consistent with this, the NMDA/AMPA
ratios derived from these currents were increased in both
genotypes (Supplementary Fig. 6d,e). Taken together, these
results indicate that CQ enhances NMDAR but not AMPAR
function at Shank2 / and WT synapses.
CQ mobilizes Zn from pre- to postsynaptic sites. Next, we
determined whether CQ-dependent NMDAR activation requires
Zn. To test this, we used two different Zn chelators with much
higher afﬁnities for Zn than CQ: Ca-EDTA (KdE10 13), which
is membrane impermeable, and TPEN (KdE10 15), which is
membrane permeable. Preincubation of slices with Ca-EDTA
before CQ treatment eliminated the CQ-dependent increase in
NMDAR activity at Shank2 / SC-CA1 synapses, as measured
by NMDA-fEPSPs (Fig. 3a). In a control experiment, Ca-EDTA
by itself had no effect on NMDA-fEPSPs (Supplementary Fig. 7a),
as reported previously24,55. TPEN also blocked CQ-dependent
NMDAR activation (Fig. 3b), although TPEN by itself caused a
small increase in the basal activity of NMDARs (Supplementary
Fig. 7b). Collectively, these ﬁndings suggest that CQ requires
Zn for NMDAR activation. In addition, the absence of an
effect of Ca-EDTA alone on NMDA-fEPSPs suggests that
CQ-dependent NMDAR activation is unlikely the result of
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disinhibition of NMDARs by CQ-mediated chelation of Zn in the
synaptic cleft.
If the Zn-ionophoric activity of CQ is the more likely candidate
mediator of NMDAR activation, this raises the question: what is
the source of Zn for NMDAR activation? One possible candidate
is the Zn pool in presynaptic neurotransmitter vesicles, a major
source of Zn in the brain that requires the ZnT3 transporter for
its maintenance21–24. In tests of this possibility using ZnT3-
deﬁcient (ZnT3 / ) mice, we found that CQ had no effect on
NMDAR activity in ZnT3 / SC-CA1 synapses (Fig. 3c),
suggesting that the presynaptic Zn pool is required for the CQ
effect. In a control experiment, we conﬁrmed that Zn signals
are indeed largely absent in the ZnT3 / hippocampus
(Supplementary Fig. 3d).
The results described to this point were obtained in experi-
ments performed without exogenous addition of Zn to brain
slices, relying on the physiological concentrations of free Zn in
the extracellular space. Previous studies have reported free Zn
concentrations in the central nervous system ofB20 nM (ref. 56),
although higher concentrations might be possible24. Here, we
tested whether increasing the extracellular Zn concentration to
250 nM affected CQ-dependent NMDAR activation. We found
that 250 nM Zn had no signiﬁcant effect on CQ-dependent
NMDAR activation at Shank2 / SC-CA1 synapses, as
measured by NMDA-fEPSPs (Fig. 3d,e). This result suggests
that additional Zn is not required for CQ-dependent NMDAR
activation at Shank2 / synapses, implying that the presynaptic
Zn pool under physiological conditions is sufﬁcient for
CQ-dependent NMDAR activation. Interestingly, 250 nM Zn
caused a signiﬁcant increase in NMDA-fEPSPs at WT synapses
(Fig. 3d,e), a differential effect that warrants further investigation.
We next attempted to visualize CQ-dependent increases in Zn
levels in postsynaptic compartments, using ZnAF-2DA, a
membrane-permeable Zn indicator that, once inside the cell, is
modiﬁed and trapped to indicate intracellular Zn levels57,58.
When WT mice were treated with CQ for 2 h, Zn signals
measured by two-photon confocal microscopy were signiﬁcantly
increased in both dendritic and cell body area of the hippocampal
CA1 region, compared with vehicle-treated controls (Fig. 4a–f;
and Supplementary Movies 1 and 2), consistent with the previous
results obtained using a regular confocal microscope58.
Finally, because CQ can bind Cu2þ (KdE10 8.9) in addition
to Zn, we tested whether the Cu2þ -binding activity of CQ also
contributed to its effects on NMDAR function. Application of
cuprizone, a selective Cu2þ chelator, to hippocampal slices
before CQ treatment did not inhibit the CQ-induced increase in
NMDAR activity (Fig. 3f), suggesting that the Cu-binding
activity of CQ is not important for NMDAR activation. Taken
together, these results suggest that CQ enhances NMDAR
function through its Zn-ionophoric, but not Zn-chelating or
Cu2þ -binding, activity, and uses mainly the presynaptic Zn pool
for NMDAR activation.
CQ activates NMDARs through postsynaptic Src. The results
described thus far suggest that CQ mobilizes Zn from presynaptic
vesicles into the synaptic cleft and postsynaptic compartments.
Zn in the synaptic cleft is unlikely to contribute to NMDAR
activation because Zn released presynaptically during neuronal
activity is known to inhibit NMDARs24, and we demonstrated
that Ca-EDTA has no effect on NMDA-fEPSPs (Supplementary
Fig. 7a).
If postsynaptic Zn delivery is an important factor, then what
would be the underlying mechanism for NMDAR activation?
Previous studies have shown that Zn binds to and inactivates
C-terminal Src kinase, a negative regulator of SFKs, which
phosphorylate and activate NMDARs27,59. In related
experiments, we found that two independent SFK inhibitors,
PP2 and SU6656, applied to hippocampal slices before CQ
treatment abolished CQ activation of NMDARs at both
Vehicle
Slice depth (5 μm)
Cell body
Cell
body
Dendrite
** ** **
Dendrite
Ve
hic
le
Ve
hic
leCQ
Ve
hic
le CQ CQ
Total
Zn
AF
-2
DA
 in
te
ns
ity
 (a
u)
Zn
AF
-2
DA
 in
te
ns
ity
 (a
u)
Zn
AF
-2
DA
 in
te
ns
ity
 (a
u)
Ve
hic
le CQ
Ratio
NS
D
en
dr
ite
 / 
ce
ll b
od
y
Zn
AF
-2
DA
 in
te
ns
ity
 ra
tio 8
6
4
2
0
40
30
20
10
0
80
60
40
20
0 0
50
100
150
Slice depth (50 μm) Slice depth (5 μm) Slice depth (50 μm)
Clioquinol
Figure 4 | CQ treatment increases Zn signals in the dendritic and cell body areas in the hippocampal CA1 region. (a–f) Mice (3–5 weeks) were injected
with CQ (30mg kg 1; i.p), or vehicle, 2 h before brain slicing, and hippocampal slices (300 mm thick) were incubated with ZnAF-2DA (40min) followed by
two-photon microscopy. Zn signals (average intensities) were measured in the indicated three square regions in the cell body, or dendritic, area of the
hippocampal CA1 region. Scale bars, 50mm (a,b). (n¼ 12 slices (6 animals) for vehicle and 12 slices (5 animals) for CQ; *Po0.05, **Po0.01, Student’s
t-test). Data in all panels with error bars represent mean±s.e.m. Au, arbitrary unit; NS, not signiﬁcant.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8168
6 NATURE COMMUNICATIONS | 6:7168 |DOI: 10.1038/ncomms8168 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Shank2 / and WT SC-CA1 synapses (Fig. 5a,b). In control
experiments, PP3, an inactive PP2 analogue, failed to block the
NMDAR activation (Fig. 5c).
To further conﬁrm that CQ enhances NMDAR function
through SFKs and to test that the subcellular site of SFK action is
indeed postsynaptic, we used the Src-inhibitory peptide
Src(40–58), which contains a sequence corresponding to Src
amino-acid residues 40–58 and selectively blocks endogenous Src
but not other SFK members59–61. Inclusion of this peptide
(0.03mgml 1) in the patch pipette during patch-clamp
recordings prevented CQ from increasing NMDAR activity at
Shank2 / and WT synapses, determined by measuring
NMDA-eEPSCs (Fig. 5d,e). In control experiments, a scrambled
Src-peptide variant (sSrc 40–58) had no effect on the
CQ-dependent increase in NMDAR activity.
In contrast to NMDARs, AMPAR function was unaffected by
the Src-inhibitory peptide, as determined from simultaneous
recordings of AMPA-eEPSCs at both WT and Shank2 /
synapses (Fig. 5d,e). Consistent with this, the CQ-dependent
increase in the NMDA/AMPA ratio determined from these
currents was blocked by the Src-inhibitory peptide, but not by the
scrambled peptide (Supplementary Fig. 8).
We also tested whether CQ treatment enhances Src activity, in
addition to NMDAR function, by immunoblot analysis of
CQ-treated hippocampal slices. We found that the levels of
tyrosine phosphorylation of Src at Y416, known to render Src
fully active59, were increased in CQ-treated WT and Shank2 /
slices, which was blocked by PP2 (Fig. 6a,b,d,e). In contrast,
tyrosine phosphorylation of Src at Y527, known to stabilize the
inactive conformation of Src59, was not affected by CQ treatment
(Fig. 6a,c,d,f), suggesting that CQ promotes Src activation
through the phosphorylation of distinct tyrosine residues.
Finally, in order to explore the involvement of other signalling
pathways in the downstream of NMDAR activation, we tested
inhibitors of MAPK kinase/MEK (PD98059) and CaMKIIa
(KN93). We found that suppression of MAPK/Erk by the
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inhibition of MAPKK/MEK in the upstream had no effect on
CQ-dependent NMDAR activation (Supplementary Fig. 9a).
Intriguingly, CaMKIIa inhibition caused a small reduction in
the levels of CQ-induced NMDAR activation after but not during
CQ treatment (Supplementary Fig. 9b), suggesting that CaMKIIa
is required for the maintenance of enhanced NMDAR function.
These results collectively suggest that the CQ-induced increase in
NMDAR function is dependent on Src, and imply that the
subcellular site of Src activation is postsynaptic.
CQ treatment improves social interaction in Tbr1þ / mice.
Finally, we considered whether CQ could rescue social interaction
deﬁcits in other mouse models of ASD in which reduced
NMDAR is associated with autistic-like behaviours. One
such model is the recently developed Tbr1-haploinsufﬁcient
(Tbr1þ / ) mouse, which has been reported to display a
reduction in social interaction that is normalized by the NMDAR
agonist D-cycloserine50. We thus tested whether CQ could also
rescue social interaction in these mice.
Tbr1þ / mice showed reduced social interaction in the three-
chamber test, compared with WT mice, and acutely injected CQ
(30mg kg 1), administered 3 h before the three-chamber test,
rescued the social interaction deﬁcits of Tbr1þ / mice, with no
effect on WT mice, as determined by time spent in exploration/
snifﬁng, time spent in chamber and the preference index derived
from exploration or chamber time (Fig. 7a–c and Supplementary
Fig. 10a–d). The positive rescue based on chamber time is
supported by the strong correlation between exploration time and
chamber time observed in Tbr1þ / mice (Supplementary
Fig. 11). CQ, however, did not affect social novelty recognition
in Tbr1þ / or WT mice, determined based on the preference for
a new stranger mouse relative to a previously encountered
stranger mouse (Fig. 7d–f and Supplementary Fig. 10e–h). These
results suggest that CQ rescues social interaction deﬁcits, but has
no effect on social novelty recognition, in Tbr1þ / mice. Taken
together with similar results obtained in Shank2 / mice, this
suggests that CQ is capable of rescuing social interaction deﬁcits
in two independent mouse models of ASD characterized by
reduced NMDAR function.
CQ restores NMDAR function at Tbr1þ / amygdalar synapses.
We hypothesized that the CQ-dependent social rescue in
Tbr1þ / mice might be associated with the restoration of reduced
NMDAR function at Tbr1þ / synapses. We ﬁrst examined
synaptic transmission at Tbr1þ / synapses in the hippocampus,
where reduced NMDAR function was observed in Shank2 /
mice. However, no signiﬁcant differences could be observed in the
electrophysiological parameters, including miniature EPSCs
(mEPSCs) in CA1 pyramidal neurons, and input–output ratio,
paired-pulse ratio and NMDA/AMPA ratio at SC-CA1 synapses
(Supplementary Fig. 12).
In contrast, principal neurons in the lateral amygdala (LA), a
brain region also enriched with glutamate- and Zn-releasing
neurons62, showed slightly increased mEPSC amplitude but not
frequency, without a change in the input–output ratio (Fig. 8a,b).
Importantly, thalamic-LA Tbr1þ / synapses showed a reduction
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in the NMDA/AMPA ratio, which was normalized by CQ
treatment (Fig. 8c,d). CQ did not cause a signiﬁcant increase in
the NMDA/AMPA ratio in WT mice. These results suggest that
Tbr1 heterozygosity causes NMDAR hypofunction selectively
in the amygdala, and its normalization is associated with the
CQ-dependent social rescue in Tbr1þ / mice.
Discussion
In the present study, we found that trans-synaptic Zn mobiliza-
tion improves social interaction in two distinct mouse models of
ASD through postsynaptic Src and NMDAR activation.
Our study suggests that CQ-dependent mobilization of Zn
from pre- to postsynaptic sites—not Zn removal after chelation—
might be useful in the treatment of ASDs. This unique trans-
synaptic Zn mobilization is supported by the following ﬁndings:
(1) CQ failed to enhance NMDAR function in ZnT3 / mice,
which lack the presynaptic Zn pool; and (2) Ca-EDTA, a
membrane-impermeable Zn chelator that should chelate Zn in
the synaptic cleft or extracellular sites, blocked CQ-dependent
NMDAR activation.
CQ can bind Cu and Fe in addition to Zn. However, CQ
appears to exert its effects through Zn interaction. A previous
study has shown that CQ can mobilize Zn and Cu but not Fe into
cytoplasmic sites in neuroblastoma cells63. In addition, our study
shows that cuprizone, a speciﬁc Cu chelator, does not block
CQ-dependent NMDAR activation. Regarding the potential
involvement of the ‘chelating’ activity of CQ, as opposed to the
‘ionophoric’ activity, we suspect it is unlikely because CQ
treatment of WT mice for 2 h did not lead to the reduction of
Zn, Cu or Fe in the brain. However, it should be pointed out that
the proposed Zn mobilization by CQ should involve Zn chelation
at presynaptic sites before Zn ions are mobilized to postsynaptic
sites through ionophoric effects.
We propose a speciﬁc mechanism that may underlie the
CQ-dependent social rescue, namely NMDAR activation through
postsynaptic Src. In support of this, CQ-dependent NMDAR
activation at Shank2 / hippocampal synapses is blocked by
two independent inhibitors of SFKs (PP2 and SU6656), as well as
the Src-inhibitory peptide Src(40–58), which acts in the
postsynaptic compartments when applied through patch pipettes.
In addition, CQ treatment increases Src phosphorylation at Y416
but not Y527. We initially expected that the phosphorylation at
Src Y527, which keeps Src at an inactive conformation, may be
reduced to activate Src because Y527 is the substrate of Zn-
inhibited C-terminal Src kinase59. On the contrary, we found an
increase in the phosphorylation of Src Y416, which is known to
render Src fully active. Although further details remain to be
studied, CQ appears to promote full activation of Src after its
initial activation by some other mechanisms.
Our study does not exclude the possibility that postsynaptic Zn
acts on targets other than SFKs and NMDARs. For instance,
a previous study has shown that Zn enhances excitatory
synaptic stabilization of Shank2/3 and synapse formation and
maturation30. Because two independent inhibitors of SFKs
and the Src-inhibitory peptide signiﬁcantly blocked the
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CQ-dependent NMDAR activation (Fig. 5), we did not explore
this possibility. It should be noted, however, that the increase in
CQ-induced NMDA-fEPSPs caused by additional Zn (250 nM)
was greater at WT synapses than at Shank2 / synapses
(Fig. 3d,e). This suggests that postsynaptic Shank2 may
contribute to Zn-dependent NMDAR activation during high
levels of neuronal activity and thus may also contribute to the
aetiology of ASDs.
Previous studies have reported the roles of CQ in the regulation
of synaptic transmission, including those from Dr Takeda’s
group57,58. The latter studies suggest that an increase in
intracellular Zn concentration in the postsynaptic side of CA1
synapses inhibits NMDAR-dependent LTP, which apparently
differ from our results that CQ has no effect on LTP at WT
SC-CA1 synapses, and that CQ enhances LTP at Shank2 /
SC-CA1 synapses (Fig. 2b). However, because Shank2 /
synapses display substantial alterations in synaptic protein
composition/modiﬁcation and synaptic transmission/plasticity45,
the CQ-dependent NMDAR activation at Shank2 / synapses
cannot be compared with the previous results. Regarding the effect
of CQ on LTP at WT synapses, the difference might stem from
that (1) previous studies used rat hippocampal slices, whereas we
used mouse ones, and (2) previous studies prepared brain slices 2 h
after i.p. injection of Zn-CQ (9.8mmol (B3mg) kg 1) and
measured LTP without CQ in the artiﬁcial CSF (ACSF), whereas
we introduced CQ (4mM) directly to slices obtained from CQ-
untreated mice during electrophysiological measurements.
Notably, an independent paper has also reported that bath
application of CQ (4mM) has no effect on LTP at SC-CA1
synapses in the mouse brain, similar to our data63. To address this
issue directly, we mimicked the method of CQ treatment reported
in Dr Takeda’s group, preparing mouse hippocampal slices 2 h
after i.p. injection of Zn-CQ (9.8mmol kg 1). However, we found
no difference between treated and untreated groups in LTP
induced by high-frequency stimulation at SC-CA1 synapses (n¼ 7
slices, 4 mice for vehicle and 7, 5 for CQ; data not shown).
Therefore, the differences may be attributable to the fact that
different animal species were used.
CQ-dependent rescue of social deﬁcits in Shank2 / and
Tbr1þ / mice was associated with CQ-dependent elevation of
NMDAR function, further supporting the hypothesis that
NMDAR hypofunction may underlie ASDs. This concept was
put forward based on the observations that D-cycloserine
improves ASD symptoms in humans and autistic-like phenotypes
in animals (reviewed in ref. 64), although further studies are
needed to verify this hypothesis.
CQ rescues social interaction in Shank2 / and Tbr1þ /
mice, but it fails to rescue social novelty recognition, repetitive
behaviour, hyperactivity or anxiety-like behaviour in Shank2 /
mice. This is reminiscent of the previous result that NMDAR
activation by D-cycloserine selectively rescues social interaction in
Shank2 / mice45. This selective rescue might be attributable to
the different nature of the circuits associated with these
behaviours, where some are reversible, or at least treatable,
whereas others are not. In line with this, NMDARs are involved
in the regulation of both neuronal development and synaptic
transmission/plasticity/signalling11,65. In addition, activity-
dependent sculpting of neuronal circuits associated with ASDs
has critical time windows66.
Finally, our study broadens the therapeutic potential of CQ.
CQ has been used as a topical antiseptic or an oral intestinal
amoebicide since 1930s, although the latter use has ceased for its
controversial association with subacute myelo-optic neuropa-
thy52. Recently, however, CQ-dependent chelation of Zn has been
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average of three consecutive responses with input stimulations of 25 mA. (n¼ 8 cells (3 animals) for WT and HT; Student’s t-test). (c) Reduced NMDA/
AMPA ratio at Tbr1þ / T-LA synapses (4–6 weeks). (n¼8 cells (5 animals) for WT and 9 (5) for HT; *Po0.05; Student’s t-test). (d) CQ restores the
NMDA/AMPA ratio at Tbr1þ / T-LA synapses but has no effect on WTsynapses (4–6 weeks). (n¼ 10 (5) for WT-V, 7 (4) for WT-C, 10 (6) for HT-V and
9 (4) for HT-C; *Po0.05; two-way analysis of variance (ANOVA) and one-way ANOVA with Tukey’s post hoc test). Data in all panels with error bars
represent mean±s.e.m. NS, not signiﬁcant.
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suggested for the treatment of neurological disorders including
Alzheimer’s disease67, Parkinson’s disease68 and Huntingtons’
disease69. Moreover, PBT2, a second-generation CQ-related
compound under clinical trials, seems to be safe and improve
cognitive deﬁcits in patients with Alzheimer’s disease67.
Therefore, our study is the ﬁrst to demonstrate the possibility
of repositioning of the FDA-approved antibiotic, CQ, to ASDs
based on a novel mechanism distinct from chelation. In addition,
CQ-dependent trans-synaptic Zn mobilization might also be
useful in other psychiatric disorders that are notable for being
caused by a decrease in NMDAR function70.
In conclusion, our study suggests that trans-synaptic Zn
mobilization rapidly improves social interaction in two indepen-
dent mouse models of ASD through Src and NMDAR activation,
and a new therapeutic potential of CQ in the treatment of ASDs.
Methods
Mice. Shank2 / mice and Tbr1þ / mice have been reported45,50. All mice
were backcrossed to a C57BL/6 background for more than 20 generations, and
housed and bred in a mouse vivarium at the Korea Advanced Institute of Science
and Technology (KAIST; Shank2 / mice) and the Academia Sinica (Tbr1þ /
mice). For breeding of Shank2 mice, we used a scheme of heterozygous (HT)HT
to produce littermate pairs of WT and KO mice. To breed Tbr1 mice, we used
offspring from HT malesWT females. Other combinations did not yield any
differences in breeding efﬁciency or behavioural phenotypes. Pups were kept with
the dam until weaning at postnatal day 21. After weaning, animals were housed in
mixed-genotype groups of 3–5 mice per cages, and randomly subjected to
electrophysiological and behavioural experiments. Animals at 3–5 weeks of age
were used for electrophysiological experiments and two-photon imaging; male
animals at 2–4 months of age were used for behavioural assays. For TFL-Zn
staining, male animals at 8 weeks (for Shank2 / mice) were used. WT
littermates were used as controls.
ZnT3 / mice, reported previously54, were maintained in the KAIST animal
facility. These mice also were backcrossed to the C57BL/6 background for more
than 10 generations. Both male and female animals at 3–5 weeks were used for
electrophysiological experiments and TFL-Zn staining (P23).
All mice were bred and maintained according to the KAIST and Academia Sinica
Animal Research Requirements, and all procedures were approved by the
Committees of Animal Research at KAIST, and at Academia Sinica. Mice were fed
ad libitum by standard rodent chow and tap water, and housed under 12 h light/dark
cycle (lights off at 1900 hours in KAIST and at 2000 hours in Academia Sinica).
Clioquinol. CQ (Calbiochem) was dissolved in dimethylsulfoxide (DMSO; Sigma)
and polyethylene glycol (Aldrich; DMSO:polyethylene glycol¼ 1: 9) to a ﬁnal
concentration of 20 g l 1. WT and Shank2 / mice (or Tbr1þ / mice) received
acute i.p. injection of CQ (30mg kg 1) or the same volume of DMSO-polyethylene
glycol mixture. The injection was performed 2 h before (Shank2 / mice and WT
littermates) or 3 h before (Tbr1þ / mice and WT littermates) behavioural assays
at the discretion of the facility.
Drug treatment scheme. We devised a within-subjects design with a 1-week
washout period (Supplementary Fig. 1a), and divided animals into two groups, vehicle-
ﬁrst and CQ-ﬁrst group, to rule out carryover effects. Each mouse received a single
acute dose of vehicle or CQ, and underwent a single behavioural task, one task per
week. Testing was conducted in dedicated behavioural test rooms during the light phase
(three-chamber test) and the dark phase (repetitive behaviours and open-ﬁeld test).
Three-chamber social interaction assay. The three-chamber social interaction
assay for Shank2mice (Shank2 / and WT littermates) and Tbr1mice (Tbr1þ /
and WT littermates) were performed45,50. In short, the assay consisted of three
phases of 10min duration: habituation, social interaction (stranger 1 versus object)
and social novelty recognition (stranger 1 versus stranger 2). Exploration was
deﬁned as instances in which WT or mutant mouse tries to sniff object/stranger, or
orients its nose towards and come close to object/stranger. Individual movement
tracks were analysed by Ethovision 10.0 (Noldus) and modiﬁed by custom-
designed software MatLab (MathWorks) to generate heat maps. Time spent in
exploration was analysed by the researcher who was blinded to the subject
genotype (in Shank2 mice), or by using the Smart Video Tracking System (Panlab,
in Tbr1 mice). In addition to exploration time, we used the preference index, which
represents a numerical difference between time spent exploring the targets
(stranger 1 versus object or stranger 2 versus stranger 1) divided by total time spent
exploring both targets45.
Repetitive behaviours. Shank2 / mice and their WT littermates in their home
cages without bedding were used to measure times spent in repetitive behaviours,
including jumping and grooming during 10min. Jumping was deﬁned as the
behaviour of a mouse where it rears on its hind legs at the corner of the cage, or
along the side walls, and jumps so that the two hind legs are simultaneously off the
ground. Grooming behaviour was deﬁned as stroking or scratching of face, head or
body with the two forelimbs, or licking body parts45. The experiments and analyses
were performed independently in a blind manner.
Open-ﬁeld test. The size of the open-ﬁeld box was 40 40 40 cm, and the
centre zone line was 13.3 cm apart from the edge. Mice were placed in the centre in
the beginning of the test, and mouse movements were recorded with a video
camera for 60min, and were analysed by Ethovision 10.0 (Noldus).
Electrophysiology. For hippocampal electrophysiological experiments, sagittal
hippocampal slices (400 mm thick for extracellular and 300mm thick for
intracellular recordings) of the mutant mice (Shank2 / mice, Tbr1þ / mice or
ZnT3 / mice) and their WT littermates were prepared using a vibratome
(Leica VT1200) in ice-cold dissection buffer containing (in mM) 212 sucrose,
25 NaHCO3, 5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 3.5 MgSO4, 10 D-glucose,
1.25 L-ascorbic acid and 2 Na-pyruvate bubbled with 95% O2/5% CO2. CA3 was
removed to prevent epileptiform activity. For amygdalar electrophysiological
experiments, coronal slices (300 mm) including the LA of Tbr1þ / mice and their
WT littermates were cut. The slices were recovered at 32 C for 1 h in normal ACSF
(in mM: 124 NaCl, 2.5 KCl, 1 NaH2PO4, 25 NaHCO3, 10 glucose, 2 CaCl2 and
2 MgSO4 oxygenated with 95% O2/5% CO2). For the recording, a single slice was
moved to and maintained in submerged-type chamber at 28 C, continuously
perfused with ACSF (2mlmin 1) saturated with 95% O2/5% CO2. Stimulation
and recording pipettes were pulled from borosilicate glass capillaries (Harvard
Apparatus) using a micropipette electrode puller (Narishege).
For extracellular recordings, mouse hippocampal slices at the age of postnatal day
21–35 were used. fEPSPs were recorded in the stratum radiatum of the hippocampal
CA1 region using pipettes ﬁlled with ACSF (1MO). fEPSP was ampliﬁed
(Multiclamp 700B, Molecular Devices) and digitized (Digidata 1440A, Molecular
Devices) for measurements. The Schaffer collateral pathway was stimulated every
20 s with pipettes ﬁlled with ACSF (0.3–0.5MO). The stimulation intensity was
adjusted to yield a half-maximal response, and three successive responses were
averaged and expressed relative to the normalized baseline. To induce LTP, high-
frequency stimulation (100Hz, 1 s) was applied after a stable baseline was acquired.
CQ (4mM) was bath applied before and after LTP induction during the whole
experimental processes. To isolate NMDAR-mediated fEPSPs, we used ACSF
containing 2mM calcium, 0.1mM magnesium and 6,7-dinitroquinoxaline-2,3-dione
(10mM, DNQX, Tocris), which inhibits AMPAR-mediated EPSPs.
Whole-cell patch-clamp recordings of hippocampal CA1 pyramidal neurons,
and of LA principal neurons in the dorsolateral division were made using a
MultiClamp 700B ampliﬁer (Molecular Devices) and Digidata 1440A (Molecular
Devices). During whole-cell patch-clamp recordings, series resistance was
monitored each sweep by measuring the peak amplitude of the capacitance
currents in response to short hyperpolarizing step pulse (5mV, 40ms); only cells
with a change in o20% were included in the analysis. For afferent stimulation of
hippocampal pyramidal neurons, the Schaffer collateral pathway was selected,
while for that of LA, the thalamic afferent pathway was stimulated. For LA
electrophysiology, brain slices were selected based on the presence of a well-
isolated, sharply deﬁned trunk (containing thalamic afferents) crossing the
dorsolateral division of the LA, which is a site of convergence of somatosensory and
auditory inputs. For NMDA/AMPA ratio experiments, mouse hippocampal slices
(P17–P25) and LA slices (4–6 weeks old) were used. The recording pipettes
(2.5–3.5MO) were ﬁlled with an internal solution containing the following (in
mM): 100 CsMeSO4, 10 TEA-Cl, 8 NaCl, 10 HEPES, 5 QX-314-Cl, 2 Mg-ATP, 0.3
Na-GTP and 10 EGTA, with pH 7.25, 295mOsm). CA1 pyramidal neurons and LA
principal neurons were voltage clamped at  70mV, and EPSCs were evoked at
every 15 s. AMPAR-mediated EPSCs were recorded at  70mV, and 30
consecutive responses were recorded after stable baseline. After recording AMPAR-
mediated EPSCs, holding potential was changed to þ 40mV to record NMDAR-
mediated EPSCs. NMDA component was measured at 60ms after the stimulation.
The NMDA/AMPA ratio was determined by dividing the mean value of 30 NMDA
components of EPSCs by the mean value of 30 AMPAR-mediated EPSC peak
amplitudes. Somatic whole-cell recording of mEPSCs were obtained in amygdalar
principal neurons at a holding potential of  70mV. TTX (1 mM) and picrotoxin
(100 mM) were added to ACSF to inhibit spontaneous action potential-mediated
synaptic currents and IPSCs, respectively. CQ (4 mM) was bath applied from
20min before and during the whole period of NMDA/AMPA ratio recording. For
measuring AMPAR-mediated and NMDAR-mediated EPSCs together upon CQ
treatment, pyramidal neurons were voltage clamped at  40mV, and EPSCs were
evoked at every 15 s. AMPAR-mediated EPSC was determined as a peak amplitude
of EPSC, and NMDAR-mediated EPSC as a component at 60ms after stimulation.
NMDA/AMPA ratio at  40mV was calculated by using both values, and
monitored during the experimental process. Src-inhibiting peptide, Src(40–58), and
its analogue, scrambled Src(40–58; ref. 61), were purchased from Peptron, and
introduced into the internal solution at a concentration of 0.03mgml 1 to observe
whether Src-inhibition affects the action of CQ. Picrotoxin (100 mM) was always
added to ACSF to block GABAA receptor-mediated currents.
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Data were acquired by Clampex 10.2 (Molecular Devices) and analysed by
Clampﬁt 10 (Molecular Devices). Drugs were purchased from Tocris (DNQX,
TPEN, PP2, PP3 and D-AP5), Abcam (PD98059) and Sigma (KN93, picrotoxin,
Ca-EDTA, cuprizone and SU6656).
ZnAF-2DA imaging. For intracellular Zn staining, two groups of WT mice (3–5
weeks) were injected with vehicle (DMSO) or CQ (30mg kg 1) 2 h before imaging.
For two-photon imaging, sagittal hippocampal slices (300 mm thick) were
immersed in 10mM ZnAF-2DA (Enzo Life Sciences) in ACSF for 40min, followed
by 1 h washout with ACSF. Zn signals were measured by using a multiphoton laser
scanning microscope system LSM 7 MP (Carl Zeiss). A total of B200 Z stack
images (0.7 mm interval;B130–180 mm total depth) were captured from each slice.
For quantiﬁcation of Zn signals, a total of 11 images at every 4.5 mm depth from the
surface (fromB5 to 50mm depth) were selected. Three regions of interest (ROIs;
squares of 33mm2) in the CA1 cell body area, or in the CA1 dendritic ﬁeld, were
analysed of Zn ﬂuorescence signals using MetaMorph (Molecular Devices).
TFL-Zn staining. Without ﬁxation, brain sections (10mm thick) were stained with
the Zn-speciﬁc dye TFL-Zn (N-(6-methoxy-8-quinolyl)-p-carbox-
ybenzoylsulfonamide (0.1mM), Calbiochem) dissolved in phosphate-buffered
saline (pH 7.2), and photographed with a digital camera linked to a ﬂuorescence
microscope (Olympus IX71; excitation, 330–385 nm; dichromatic, 400 nm; and
barrier, 420 nm). Fluorescence signals were obtained using an image programme
(Image-Pro Insight, Media Cybernetics, Silver Spring, MD). Images of ﬁve con-
secutive hippocampal slices from an individual brain were quantiﬁed using
MetaMorph (Molecular Devices). ROIs were deﬁned as three to ﬁve squares
(50 50 mm2) in WT and Shank2 / hippocampal DG, CA3 and CA1 regions (5,
3 and 5 squares, respectively). For quantiﬁcation, the total ﬂuorescence from a
Shank2 / ROI was normalized to that from an equivalent WT ROI.
Src immunoblot analysis. For immunoblotting of Src proteins, WT and
Shank2 / sagittal hippocampal slices (400 mm thick; 3–5 weeks) were prepared
using a vibratome (Leica VT1200). After recovery at 37 C for 1 h in normal ACSF
supplemented with 250 nM ZnCl2, slices were treated with CQ, or vehicle (DMSO),
for 20min, in the presence or absence of PP2. After treatments, the slices were
homogenized in 100ml ice-cold homogenization buffer (0.32M sucrose, 10mM
HEPES, pH 7.4, 2mM EDTA, protease inhibitors and phosphatase inhibitors) per
each slice, and subjected to immunoblot analysis and quantiﬁcation using Odyssey
Fc Imaging System (LI-COR). The following antibodies were purchased: Src,
phosphor-Src (Tyr-416; 1:1,000 dilution) and phosphor-Src (Tyr-527; Cell Sig-
naling; 1:1,000 dilution). Full-size immunoblot images for Fig. 6 are shown in
Supplementary Fig. 13.
Crude synaptosomes. Crude synaptosomes from Shank2 / mice were pre-
pared as described45. Brieﬂy, mouse brains (2 months old) were homogenized in
ice-cold homogenization buffer (0.32M sucrose, 10mM HEPES, pH 7.4, 2mM
EDTA, protease inhibitors and phosphatase inhibitors). The homogenates were
centrifuged at 900g for 10min. The resulting supernatant was centrifuged again at
12,000g for 15min. The pellet was resuspended in homogenization buffer and
centrifuged at 13,000g for 15min (the resulting pellet is P2; crude synaptosomes).
This sample was immunoblotted with ZnT3 antibodies (SYSY).
Metal analysis. WT and Shank2 / mice (2–3 months) were treated with CQ
(30mg kg 1), or DMSO, by i.p. injection 2 h before brain preparation and sub-
sequent whole-brain metal analysis by inductively coupled plasma mass
spectrometry.
Statistical analysis. We randomly performed all the behaviour experiments,
ZnAF-2DA and TFL-Zn imaging, and metal analysis by researchers blind to the
identity of the animals, and analysed the data in a blind manner. Data collection
and analysis for slice electrophysiology and immunoblotting were performed
randomly, but not blind to the conditions of the experiments. Statistical analyses
were performed using Prism GraphPad (version 6.05) software, and details of the
results are described Supplementary Data 1. No statistical methods were used to
predetermine sample sizes, but our sample sizes are similar to those reported in
previous related publications45,50. An outlier was deﬁned as a value outside the
mean±3 s.d.
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